CDX-2 and HER-3 Expression in Canine Gastric and Colorectal Adenocarcinomas

Journal of Comparative Pathology

Volumn 145, Issue 1, 2011, Pages 12-19

  Doster, A R ^a   Yhee, J Y ^b   Kim, J H ^b   Im, K S ^b   Sur, J H ^b  

^a UNIVERSITY OF NEBRASKA LINCOLN   (United States)

^b Konkuk University   (South Korea)

Author keywords

CDX 2; Dog; Gastrointestinal adenocarcinoma; HER 3; Immunohistochemistry

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 3; TRANSCRIPTION FACTOR CDX2;

ARTICLE; COLON ADENOCARCINOMA; COLON MUCOSA; CONTROLLED STUDY; CYTOPLASM; DOG; FEMALE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECTUM CARCINOMA; STOMACH ADENOCARCINOMA; STOMACH EPITHELIUM;

ADENOCARCINOMA; ANIMALS; COLORECTAL NEOPLASMS; DOG DISEASES; DOGS; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HOMEODOMAIN PROTEINS; IMMUNOHISTOCHEMISTRY; MALE; RECEPTOR, ERBB-3; STOMACH NEOPLASMS; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL;

CANIS FAMILIARIS;

EID: 79956033070     PISSN: 00219975     EISSN: 15323129     Source Type: Journal    
DOI: 10.1016/j.jcpa.2010.11.007     Document Type: Article

References (30)

1. Barbareschi M., Murer B., Colby T.V., Chilosi M., Macri E., et al. CDX-2 homeobox gene expression is a reliable marker of colorectal adenocarcinoma metastases to the lungs. The American Journal of Surgical Pathology 2003, 27:141-149.
2. Church E.M., Mehlhaff C.J., Patnaik A.K. Colorectal adenocarcinoma in dogs: 78 cases (1973-1984). Journal of the American Veterinary Medical Association 1987, 191:727-730.
3. Cunningham M.P., Essapen S., Thomas H., Green M., Lovell D.P., et al. Coexpression of the IGF-IR, EGFR and HER-2 is common in colorectal cancer patients. International Journal of Oncology 2006, 28:329-335.
4. De Lott L.B., Morrison C., Suster S., Cohn D.E., Frankel W.L. CDX2 is a useful marker of intestinal-type differentiation: a tissue microarray-based study of 629 tumors from various sites. Archives of Pathology and Laboratory Medicine 2005, 129:1100-1105.
5. Graus-Porta D., Beerli R.R., Daly J.M., Hynes N.E. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO Journal 1997, 16:1647-1655.
6. Grivas P.D., Antonacopoulou A., Tzelepi V., Sotiropoulou-Bonikou G., Kefalopoulou Z., et al. HER-3 in colorectal tumourigenesis: from mRNA levels through protein status to clinicopathologic relationships. European Journal of Cancer 2007, 43:2602-2611.
7. Hayashi M., Inokuchi M., Takagi Y., Yamada H., Kojima K., et al. High expression of HER3 is associated with a decreased survival in gastric cancer. Clinical Cancer Research 2008, 14:7843-7849.
8. Head K.W., Else R.W., Dubielzig R.R. Tumors of the alimentary tract. Tumors in Domestic Animals 2002, 401-481. Blackwell Publishing Company, Ames. 4th Edit. D.J. Meuten (Ed.).
9. Hinoi T., Tani M., Lucas P.C., Caca K., Dunn R.L., et al. Loss of CDX2 expression and microsatellite instability are prominent features of large cell minimally differentiated carcinomas of the colon. American Journal of Pathology 2001, 159:2239-2248.
10. Kapitanovic S., Radosevic S., Slade N., Kapitanovic M., Andelinovic S., et al. Expression of erbB-3 protein in colorectal adenocarcinoma: correlation with poor survival. Journal of Cancer Research and Clinical Oncology 2000, 126:205-211.
11. Kiguchi K., Carbajal S., Chan K., Beltran L., Ruffino L., et al. Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma. Cancer Research 2001, 61:6971-6976.
12. Kountourakis P., Pavlakis K., Psyrri A., Rontogianni D., Xiros N., et al. Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas. BMC Cancer 2006, 6:46.
13. Kunii K., Davis L., Gorenstein J., Hatch H., Yashiro M., et al. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Research 2008, 68:2340-2348.
14. Lee J.C., Wang S.T., Chow N.H., Yang H.B. Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery. European Journal of Cancer 2002, 38:1065-1071.
15. Lingeman C.H., Garner F.M., Taylor D.O. Spontaneous gastric adenocarcinomas of dogs: a review. Journal of the National Cancer Institute 1971, 47:137-153.
16. Mallo G.V., Soubeyran P., Lissitzky J.C., Andre F., Farnarier C., et al. Expression of the Cdx1 and Cdx2 homeotic genes leads to reduced malignancy in colon cancer-derived cells. Journal of Biological Chemistry 1998, 273:14030-14036.
17. Mazziotta R.M., Borczuk A.C., Powell C.A., Mansukhani M. CDX2 immunostaining as a gastrointestinal marker: expression in lung carcinomas is a potential pitfall. Applied Immunohistochemistry and Molecular Morphology 2005, 13:55-60.
18. Moskaluk C.A., Zhang H., Powell S.M., Cerilli L.A., Hampton G.M., et al. Cdx2 protein expression in normal and malignant human tissues: an immunohistochemical survey using tissue microarrays. Modern Pathology 2003, 16:913-919.
19. Nathanson D.R., Culliford A.T., Shia J., Chen B., D'Alessio M., et al. HER 2/neu expression and gene amplification in colon cancer. International Journal of Cancer 2003, 105:796-802.
20. Osako T., Miyahara M., Uchino S., Inomata M., Kitano S., et al. Immunohistochemical study of c-erbB-2 protein in colorectal cancer and the correlation with patient survival. Oncology 1998, 55:548-555.
21. Prigent S.A., Gullick W.J. Identification of c-erbB-3 binding sites for phosphatidylinositol 3'-kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO Journal 1994, 13:2831-2841.
22. Saad R.S., Cho P., Silverman J.F., Liu Y. Usefulness of Cdx2 in separating mucinous bronchioloalveolar adenocarcinoma of the lung from metastatic mucinous colorectal adenocarcinoma. American Journal of Clinical Pathology 2004, 122:421-427.
23. Shin H.R., Jung K.W., Won Y.J., Park J.G. 2002 annual report of the Korea central cancer registry: based on registered data from 139 hospitals. Cancer Research and Treatment 2004, 36:103-114.
24. Silberg D.G., Swain G.P., Suh E.R., Traber P.G. Cdx1 and cdx2 expression during intestinal development. Gastroenterology 2000, 119:961-971.
25. Srinivasan R., Benton E., McCormick F., Thomas H., Gullick W.J. Expression of the c-erbB-3/HER-3 and c-erbB-4/HER-4 growth factor receptors and their ligands, neuregulin-1 alpha, neuregulin-1 beta, and betacellulin, in normal endometrium and endometrial cancer. Clinical Cancer Research 1999, 5:2877-2883.
26. Vang R., Gown A.M., Wu L.S., Barry T.S., Wheeler D.T., et al. Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7. Modern Pathology 2006, 19:1421-1428.
27. Werling R.W., Yaziji H., Bacchi C.E., Gown A.M. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. American Journal of Surgical Pathology 2003, 27:303-310.
28. Wiseman S.M., Makretsov N., Nielsen T.O., Gilks B., Yorida E., et al. Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival. Cancer 2005, 103:1770-1777.
29. Wolf J.C., Ginn P.E., Homer B., Fox L.E., Kurzman I.D. Immunohistochemical detection of p53 tumor suppressor gene protein in canine epithelial colorectal tumors. Veterinary Pathology 1997, 34:394-404.
30. Yamamoto S., Mochizuki H., Hase K., Yamamoto T., Ohkusa Y., et al. Assessment of clinicopathologic features of colorectal mucinous adenocarcinoma. American Journal of Surgical Pathology 1993, 166:257-261.